ALT The newly discovered antibiotic Clovibactin from unculturable bacteria, also known as 'microbial dark matter. Clovibactin uses an unusual cage-like binding motif to tightly wrap around immutable pyrophosphate of cell wall precursors, but ignores the variable sugar-peptide part. This enables Clovibactin to target different, indispensable cell wall precursors (Lipid II, Lipid III, C55PP) in bacterial cell membranes, and it makes the drug extremely robust to the development of antimicrobial resistance. Clovibactin does even more: Upon target binding, it assembles to fibrils on the membrane surface. These fibrils help to stably binds the target as long as it takes. Altogether, Clovibactin is a promising lead for the development of next-generation therapeutics with a long clinical lifetime. PS: The name comes from the binding motif - 'Klouvi' means cage in Greek. Illustration by Gloria Fuentes from 'The Visual Thinker'